2022-12-28| M&ASpecial

GeneOnline’s Pick: Top 10 M&A Deals in 2022

by Richard Chau
Share To
2022 is an eventful year in terms of restructuring the global biomedical industry. Many major pharmaceutical companies are benefiting from the huge demand for pandemic prevention brought about by COVID-19, and have generated impressive revenues from vaccines, pharmaceuticals, and products related to testing equipment. This is why they continue to allocate funds to further R&D investments in 2022, or to reorganize their product lines through licensing, strategic alliances, and mergers and acquisitions.
Global biotech M&A market in 2022 experienced its slowest pace since 2018, with a downward trend in terms of both the number of deals and transaction amounts. According to statistics from PwC as of mid-November 2022, the number of deals in the pharmaceutical and life sciences sector in 2022 is 266, marking a 28% decrease compared to 2021, and the total deal value is $137 billion, registering a 49% reduction from the previous year. Nonetheless, this does not necessarily mean that the global biotech investment market is shrinking. The largest biotech M&A deal of the year comes at the end of 2022 - Amgen’s $27.8 billion acquisition of Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases.

It's free! Log in now to read

Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
Scroll to Top